To include your compound in the COVID-19 Resource Center, submit it here.

MorphoSys planning BLA for DLBCL candidate on Phase II data

MorphoSys AG (Xetra:MOR; Pink:MPSYY) said it discussed with FDA the possibility of expedited regulatory submission and approval for its MOR208 (MOR00208) to treat relapsed or refractory diffuse large B cell

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers